Market news — every asset we track

Assets

KRRO

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for...

Aug 27Barchart.com

KRRO

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel...

Aug 14Barchart.com

KRRO

Korro Bio director Jean Francois Formela sells $29,916 in shares

Aug 13Investing.com

KRRO

Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock

Aug 13Investing.com

KRRO

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Aug 10Yahoo Finance

KRRO

Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP) and Korro Bio (KRRO)

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

Aug 9theglobeandmail.com

CRBP

KRRO

Korro Bio Refines Capital Structure with Exchange Agreement

Detailed price information for Korro Bio Inc (KRRO-Q) from The Globe and Mail including charting and trades.

Aug 7The Globe and Mail

KRRO

Raymond James reiterates Korro Bio stock rating on hyperammonemia outlook

Aug 7Investing.com

KRRO

Korro Bio earnings beat by $0.24, revenue topped estimates

Aug 6Investing.com

KRRO

Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?

Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Jul 8Yahoo Finance

KRRO

Korro Bio Insider Sold Shares Worth $1,542,970, According to a Recent SEC Filing

Jul 8Yahoo Finance

KRRO

This is the newest page. Registered accounts read further back.